InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of High Risk for CAR-T Treatment Failure By Ogkologos - May 5, 2025 251 0 Facebook Twitter Google+ Pinterest WhatsApp A valuable tool for point-of-care clinical decision-making in patients with non-Hodgkin lymphoma Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Zenocutuzumab Approved to Treat Lung and Pancreatic Cancers with Rare Genetic... March 26, 2025 New on NCI’s Websites for March 2019 March 29, 2019 EMA Recommends Granting a Marketing Authorisation for Inavolisib June 26, 2025 What to Do If You’ve Been Diagnosed With Cancer in the... June 13, 2023 Load more HOT NEWS Exercising Safely During Breast Cancer Treatment: What to Know Treatment Benefit with Quizartinib, a Potent and Specific FLT3 Inhibitor for... ScottishPower help us shine a light on air pollution and cancer Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows
